Low Graft Invariant Natural Killer T-Cell Dose Is a Risk Factor for Cytomegalovirus Reactivation After Allogeneic Hematopoietic Cell Transplantation

Transplant Cell Ther. 2022 Aug;28(8):513.e1-513.e4. doi: 10.1016/j.jtct.2022.05.011. Epub 2022 May 14.

Abstract

Cytomegalovirus (CMV) reactivation is common after allogeneic hematopoietic cell transplantation (HCT) and may result in fatal CMV disease. Invariant natural killer T (iNKT) cells are potent modulators of the immune system preventing graft-versus-host disease while promoting graft-versus-leukemia effects. It is thought that iNKT cells selectively influence mediators of both innate and adaptive immunity. Here, we investigated the impact of graft iNKT cells on CMV reactivation in patients undergoing allogeneic HCT. We found a significantly decreased cumulative incidence of CMV reactivation in patients with higher numbers of iNKT cells in the allograft. Therefore iNKT-cell-enriched grafts or adoptive transfer of iNKT cells are compelling cytotherapeutic strategies to improve outcomes after allogeneic HCT.

Keywords: Hematopoietic cell transplantation; Infectious complications; Innate immunity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytomegalovirus
  • Cytomegalovirus Infections*
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Natural Killer T-Cells*
  • Risk Factors